Published in Am J Epidemiol on May 01, 2005
Azithromycin and the risk of cardiovascular death. N Engl J Med (2012) 8.18
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 4.70
ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med (2011) 3.12
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol (2009) 2.33
Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf (2006) 1.99
Limits of observational data in determining outcomes from cancer therapy. Cancer (2008) 1.97
Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc (2011) 1.76
The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf (2011) 1.74
Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol (2011) 1.72
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood (2010) 1.67
Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum (2012) 1.58
Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care (2007) 1.56
The role of the c-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf (2010) 1.45
Prevalence of psychosis in black ethnic minorities in Britain: analysis based on three national surveys. Soc Psychiatry Psychiatr Epidemiol (2014) 1.43
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis (2011) 1.42
Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther (2007) 1.42
Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf (2012) 1.32
Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiol Drug Saf (2010) 1.31
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf (2011) 1.30
Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev (2006) 1.20
Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf (2010) 1.10
Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med (2014) 1.06
Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf (2013) 1.05
Review of methods for handling confounding by cluster and informative cluster size in clustered data. Stat Med (2014) 1.03
On the joint use of propensity and prognostic scores in estimation of the average treatment effect on the treated: a simulation study. Stat Med (2013) 0.99
Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care (2013) 0.97
Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ (2014) 0.92
Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations. Pharmacoepidemiol Drug Saf (2014) 0.91
Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol (2013) 0.90
Data for cancer comparative effectiveness research: past, present, and future potential. Cancer (2012) 0.89
Physicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System. Arthritis Care Res (Hoboken) (2013) 0.88
Colorectal cancer after start of nonsteroidal anti-inflammatory drug use. Am J Med (2006) 0.86
Propensity score calibration in the absence of surrogacy. Am J Epidemiol (2012) 0.86
Costs of treating children with complicated pneumonia: a comparison of primary video-assisted thoracoscopic surgery and chest tube placement. Pediatr Pulmonol (2010) 0.85
Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int (2009) 0.85
Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiol Drug Saf (2012) 0.85
Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. BMC Med Res Methodol (2013) 0.83
Performance of time-dependent propensity scores: a pharmacoepidemiology case study. Pharmacoepidemiol Drug Saf (2014) 0.82
Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf (2013) 0.81
Childbearing is not associated with young women's long-term obesity risk. Obesity (Silver Spring) (2013) 0.80
Association between anti-TNF-α therapy and all-cause mortality. Pharmacoepidemiol Drug Saf (2012) 0.80
Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment. Community Ment Health J (2014) 0.79
The role of secondary cytoreductive surgery in patients with recurrent epithelial ovarian, tubal, and peritoneal cancers: a comparative effectiveness analysis. Oncologist (2012) 0.78
Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. Emerg Themes Epidemiol (2016) 0.77
Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ (2016) 0.77
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study. Chin J Cancer (2016) 0.75
Cardiovascular safety of celecoxib in acute myocardial infarction patients: a nested case-control study. Heart Int (2009) 0.75
Conducting Privacy-Preserving Multivariable Propensity Score Analysis When Patient Covariate Information Is Stored in Separate Locations. Am J Epidemiol (2017) 0.75
The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control. Am J Epidemiol (2017) 0.75
Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study. Pediatrics (2016) 0.75
Covariate balance in a Bayesian propensity score analysis of beta blocker therapy in heart failure patients. Epidemiol Perspect Innov (2009) 0.75
ISPOR Health Policy Council proposed Good Research Practices for comparative effectiveness research: benefit or harm? Value Health (2009) 0.75
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol (1996) 20.25
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83
Simulation study of confounder-selection strategies. Am J Epidemiol (1993) 12.76
The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med (1998) 9.19
Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology (1995) 8.36
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol (2001) 7.04
Stratification by a multivariate confounder score. Am J Epidemiol (1976) 4.58
Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med (2002) 4.38
Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol (2003) 4.27
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation (2003) 2.73
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol (2002) 2.54
Paradoxical relations of drug treatment with mortality in older persons. Epidemiology (2001) 2.52
Should we adjust for covariates in nonlinear regression analyses of randomized trials? Control Clin Trials (1998) 2.40
Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology (2001) 2.39
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension (2002) 2.16
The renal effects of nonsteroidal anti-inflammatory drugs in older people: findings from the Established Populations for Epidemiologic Studies of the Elderly. J Am Geriatr Soc (1999) 2.12
The association between hospital type and mortality and length of stay: a study of 16.9 million hospitalized Medicare beneficiaries. Med Care (2000) 1.78
Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med (2001) 1.74
Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity score. J Clin Epidemiol (1989) 1.58
Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol (2002) 1.57
Modeling treatment effects on binary outcomes with grouped-treatment variables and individual covariates. Am J Epidemiol (2002) 1.48
Prognostic models and the propensity score. Int J Epidemiol (1995) 1.36
Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA (1994) 1.24
Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. JAMA (1990) 1.05
The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol (2003) 1.00
Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med (2001) 0.98
The role of eicosanoids, cyclooxygenases, and nonsteroidal anti-inflammatory drugs in colorectal tumorigenesis and chemoprevention. J Clin Gastroenterol (2002) 0.88
The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf (2000) 0.86
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA (2008) 6.63
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 4.70
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
The rise and fall of epidemiology, 1950-2000 A.D. 1981. Int J Epidemiol (2007) 4.56
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07
Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med (2006) 3.75
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Altitude and all-cause mortality in incident dialysis patients. JAMA (2009) 3.62
Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med (2010) 3.57
Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med (2013) 2.77
Internet marketing of herbal products. JAMA (2003) 2.77
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74